Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection

J Clin Med. 2022 Aug 30;11(17):5086. doi: 10.3390/jcm11175086.

Abstract

Helicobacter pylori (Hp) is a prevalent organism infecting almost half the global population. It is a significant concern, given its associated risk of gastric cancer, which is the third leading cause of cancer death globally. Infection can be asymptomatic or present with dyspeptic symptoms. It may also present with alarm symptoms in the case of progression to cancer. Diagnosis can be achieved non-invasively (breath tests, stool studies, or serology) or invasively (rapid urease test, biopsy, or culture). Treatment involves acid suppression and regimens containing several antibiotics and is guided by resistance rates. Eradication is essential, as it lowers the risk of complications and progression to cancer. Follow-up after eradication is similarly important, as the risk of cancer progression remains. There have been many recent advances in both diagnosis and treatment of Hp. In particular, biosensors may be effective diagnostic tools, and nanotechnology, vaccines, and potassium-competitive acid blockers may prove effective in enhancing eradication rates.

Keywords: Helicobacter pylori; bismuth; dyspepsia; gastric cancer; peptic ulcer disease; triple therapy; vonoprazan.

Publication types

  • Review

Grants and funding

This research received no external funding.